Search - tctmd.com

Displaying 101 - 120 of 415

Sort: Relevancy | Date

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

January 2023 News Roundup

News Opinion CV Team Dispatch

January 2023 News Roundup

January 16, 2023

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

News Conference News PCR London Valves 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

December 07, 2022

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

News Daily News

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

November 21, 2022

Another DOAC Fails in the Setting of Mechanical Heart Valves

News Daily News

Another DOAC Fails in the Setting of Mechanical Heart Valves

September 28, 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

News Conference News TCT 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

Michael O'Riordan

September 22, 2022

Thrombosis, HALT, and Bleeding Risk

Presentation TCT 2022

Thrombosis, HALT, and Bleeding Risk

Presenter: Gagan D. Singh

September 19, 2022

TCT 361: On the Likelihood of Leaflet Thrombosis following Transcatheter Pulmonary Valve Replacement

Presentation TCT 2022

TCT 361: On the Likelihood of Leaflet Thrombosis following Transcatheter Pulmonary Valve Replacement

Presenter: Mina Shafiei

September 19, 2022

TCT 360: The Importance of Leaflet Design in Initiation and Growth of Leaflet Thrombosis in Transcatheter Aortic Valves

Presentation TCT 2022

TCT 360: The Importance of Leaflet Design in Initiation and Growth of Leaflet Thrombosis in Transcatheter Aortic Valves

Presenter: Ali Azadani

September 19, 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

News Conference News TVT 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Michael O'Riordan

June 10, 2022

Valve thrombosis remains a big issue: Data on TAVI and surgical valve

Presentation TVT 2022

Valve thrombosis remains a big issue: Data on TAVI and surgical valve

Presenter: Blake Gardner

June 09, 2022

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

News Conference News EuroPCR 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

Yael L. Maxwell

May 23, 2022

Better Durability With Self-Expanding TAVI? Clues From UK TAVI

News Conference News EuroPCR 2022

Better Durability With Self-Expanding TAVI? Clues From UK TAVI

May 18, 2022

Fewer Lead-Related Complications With Subcutaneous ICD: ATLAS S-ICD

News Conference News HRS 2022

Fewer Lead-Related Complications With Subcutaneous ICD: ATLAS S-ICD

April 30, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

News Daily News

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

Michael O'Riordan

March 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.